Back to search
FDAFDA · Food and drugs·Recall number D-1349-2022

Azacitidine for Injection, 100 mg Lyophilized Powder, Single-Dose Vials, Rx Only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 India. Manufactured for BluePoint Laboratories. NDC 68001-0313-56

Published August 24, 2022 · Recall initiated: July 27, 2022

Summary

FDA records drug Class III recall D-1349-2022, published August 24, 2022 and initiated July 27, 2022. Recalling firm: Amerisource Health Services LLC; Status: Terminated; Reported quantity: 4,160 vials; Lot: Lot #: FE22001A, Exp. Date 01/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
Nationwide within the USA
Lot
Lot #: FE22001A, Exp. Date 01/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Azacitidine for Injection, 100 mg Lyophilized Powder, Single-Dose Vials, Rx Only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 India. Manufactured for BluePoint Laboratories. NDC 68001-0313-56 recalled?

Yes. FDA published recall D-1349-2022 on August 24, 2022. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter